Recent advancements in liquid biopsies have demonstrated the potential of cfDNA as a universal, minimally invasive sample type in cancer prognosis, diagnosis, and prenatal testing 1. In parallel, the ...

Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer We developed a ddPCR assay to sensitively detect tumor-derived hypermethylated RASSF1A ...

Study findings indicate that droplet digital polymerase chain reaction (ddPCR) may be more accurate than real-time quantitative PCR in measuring minimal residual disease (MRD) among pediatric patients ...

A recent review took a look at the promise of measuring circulating tumor DNA (ctDNA) with digital-droplet PCR (ddPCR) in pancreatic ductal adenocarcinoma (PDAC) as the landscape of this cancer ...

Droplet digital polymerase chain reaction (ddPCR) technology is emerging as an efficient, accurate, and precise way to measure transgene copy numbers. With it, scientists may screen for clonal ...

Bio-Rad Laboratories, Inc. BIO announced that the performance of its QX200 Droplet Digital polymerase chain reaction (PCR) (ddPCR) System for the clinical detection of SARS-CoV-2 was proved to be more ...

A recent study published online in the Journal of Molecular Diagnostics demonstrated that Droplet Digital PCR (ddPCR) technology can be used to detect mutations in a region of our DNA that is linked ...

Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study Plasma cfDNA and pathology specimens of 36 patients were analyzed. Agreement ...

Bio-Rad (CA, USA), a clinical diagnostics products company, has launched a new ddPCR kit designed to assess AAV vector quality for gene therapy development. Vericheck ddPCR Empty-Full Capsid Kit can ...

In recent years, liquid biopsy approaches have emerged as powerful tools in oncology, enabling non‑invasive, real‑time insights into tumor dynamics. Among these technologies, droplet digital PCR ...

In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...